Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function

An Open-label, Multi-center Trial to Evaluate the Pharmacokinetic Profile of Glepaglutide After a Single Subcutaneous Injection in Subjects With Varying Degrees of Renal Function

This is two stage design, open-label, multi-center, non-randomized trial evaluating the PK of a single, subcutaneous dose of 10 mg glepaglutide in subjects with varying degrees of renal function. The renal function will be calculated by the estimated glomerular filtration rate (eGFR) according to the Modification of Diet in Renal Disease (MDRD) equation.

Study Overview

• Status: Completed
• Conditions: Renal Impairment
• Intervention / Treatment: Drug: Glepaglutide

• Study Type: Interventional
• Enrollment (Actual): 16
• Phase: Phase 1

Contacts and Locations

Study Locations

• Hungary
  • Budapest, Hungary, 1115
    • Szent Imre Egyetemi Oktatokorhaz
  • Budapest, Hungary, 1077
    • Fázis I-es Klinikai Farmakológiai
• Poland
  • Kraków, Poland, 31-559
    • Specjalistyczne Centrum Medyczne - Prywatny Szpital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• All subjects

  1. Able to understand and willing to sign the informed consent
  2. eGFR values as defined in in the arms
  3. Willing and able to comply with the study requirements
  4. Male and female subjects age 18 to 70 years (both inclusive) at the time of informed consent
  5. BMI 20.0 - 30.0 kg/m2 both inclusive

  6. Must be willing to comply with the contraception, sperm-donation requirements, and study restrictions.

     Renally Impaired Subjects (in Addition)

  7. Subject has a stable disease, including disease(s) associated with renal impairment, under medical control (ie, no changes in medication within 30 days prior to study drug administration). Stable renal impairment, defined as no clinically significant change in disease status within 3 months before screening.

Exclusion Criteria:

All Subjects

1. Suspicion of hypersensitivity, intolerance, or allergy to glepaglutide
2. History of alcohol or drug abuse
3. Clinically relevant abnormal medical history, abnormal findings on physical examination, vital signs, clinically significant abnormalities on 12-lead ECG, or laboratory tests at Screening that the Investigator judges as likely to interfere with the objectives of the study or the safety of the subject except for conditions associated with renal impairment in subjects with renal impairment
4. Uncontrolled treated/untreated hypertension (defined as a mean of 3 repeated measurements for systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 110 mmHg); current or documented history of repeated clinically significant hypotension or severe episodes of orthostatic hypotension (systolic blood pressure < 90 mmHg and/or diastolic blood pressure < 50 mmHg)
5. Acute illness within 14 days prior to dosing unless mild in severity and approved by the Investigator and Sponsor's medical representative
6. Presence of active infection requiring antibiotics. Ingestion of alcohol within 72 hours prior to study drug administration and during PK sampling period including Follow-Up
7. Participation in another investigational drug study within 30 days prior to study drug administration or exposure to more than three new investigational agents within 12 months prior to study drug administration
8. Previous exposure to GLP-1, GLP-2, human growth hormone, somatostatin, or analogues thereof within 3 months prior to Screening. Use of dipeptidyl peptidase-4 inhibitors within 3 months prior to Screening
9. Previous exposure to glepaglutide
10. Donation or loss of more than 450 mL blood during the 3 months before the start of Screening
11. Female subjects who are breastfeeding, pregnant, or planning to become pregnant during the study
12. Positive serology for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV) or human immunodeficiency virus antibodies (anti-HIV)-1/2, unless the absence of an active hepatitis B/C infection is confirmed by a polymerase chain reaction (PCR) test, at Screening
13. Positive urine screen of drugs of abuse (if not due to concomitant medication) or alcohol breath test at Screening and/or Day -1

14. Legal incapacity or limited legal capacity

    Renally Impaired Subjects (in Addition)

15. Acute renal failure (as judged by the Investigator)
16. Renal impairment requiring dialysis
17. History of kidney transplant regardless of functionality
18. Serum albumin concentration <25 g/L
19. Haemoglobin concentration <100 g/L

20. Medications known to affect the elimination of serum creatinine (e.g., trimethoprim or cimetidine) and competitors of renal tubular secretion (e.g., probenecid) within 60 days prior to study drug administration

    Subjects With Normal Renal Function (in Addition)

21. Significant medical history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, haematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator -

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group 1: ESRD subjects not on dialysis or severe RI; subjects with eGFR <15 mL/min/1.73 m2) or (eGFR 15 to <30 mL/min/1.73 m2)	Drug: Glepaglutide; Single dose of Glepaglutide 10 mg; Other Names: ZP1848
Experimental: Group 2: normal renal function; subjects with eGFR ≥90 mL/min/1.73 m2	Drug: Glepaglutide; Single dose of Glepaglutide 10 mg; Other Names: ZP1848
Experimental: Group 3: moderate RI; subjects with eGFR 30 to <60 mL/min/1.73 m2	Drug: Glepaglutide; Single dose of Glepaglutide 10 mg; Other Names: ZP1848
Experimental: Group 4: mild RI; subjects with eGFR 60 to <90 mL/min/1.73 m2	Drug: Glepaglutide; Single dose of Glepaglutide 10 mg; Other Names: ZP1848

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetic Variables	AUC0-168 area under the concentration-time curve (AUC) from time 0 to 168 hours Cmax maximum observed plasma concentration	11 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety Variables	Number of subject with AE/SAE as a measure of safety and tolerability	11 days

Collaborators and Investigators

• Sponsor: Zealand Pharma

Study record dates

Study Major Dates

• Study Start (Actual): December 10, 2019
• Primary Completion (Actual): July 14, 2020
• Study Completion (Actual): July 14, 2020

Study Registration Dates

• First Submitted: November 25, 2019
• First Submitted That Met QC Criteria: November 25, 2019
• First Posted (Actual): November 26, 2019

Study Record Updates

• Last Update Posted (Actual): November 18, 2020
• Last Update Submitted That Met QC Criteria: November 17, 2020
• Last Verified: March 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Kidney Diseases; Urologic Diseases; Renal Insufficiency
• Other Study ID Numbers: ZP1848-18131; 2019-001466-15 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No